KR900015726A - 이뇨제, 소염제 및 뇌혈제관제로서의 7-치환 아미노-8-치환 카르보닐-메틸아미노-1-옥사스피로[4,5]데칸 - Google Patents

이뇨제, 소염제 및 뇌혈제관제로서의 7-치환 아미노-8-치환 카르보닐-메틸아미노-1-옥사스피로[4,5]데칸 Download PDF

Info

Publication number
KR900015726A
KR900015726A KR1019900005561A KR900005561A KR900015726A KR 900015726 A KR900015726 A KR 900015726A KR 1019900005561 A KR1019900005561 A KR 1019900005561A KR 900005561 A KR900005561 A KR 900005561A KR 900015726 A KR900015726 A KR 900015726A
Authority
KR
South Korea
Prior art keywords
carbon atoms
alkyl
compound
hydrogen
pharmaceutically acceptable
Prior art date
Application number
KR1019900005561A
Other languages
English (en)
Other versions
KR0149491B1 (ko
Inventor
크리스토퍼 호르웰 데이비드
씨. 리스 데이비드
Original Assignee
크리스틴 에이. 트러트웨인
워너-램버트 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 크리스틴 에이. 트러트웨인, 워너-램버트 캄파니 filed Critical 크리스틴 에이. 트러트웨인
Publication of KR900015726A publication Critical patent/KR900015726A/ko
Priority to KR1019980015878A priority Critical patent/KR0150182B1/ko
Application granted granted Critical
Publication of KR0149491B1 publication Critical patent/KR0149491B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

내용 없음.

Description

이뇨제, 소염제 및 노혈제관제로서의 7-치환 아미노-8-치환 카르보닐-메틸아미노-1-옥사스피로[4,5]데칸
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 다음 일반식 (I)의 화합물 및 그의 제약상 허용되는 염의 유효 치료량을 뇌혈관 장해의 치료를 요하는 환자에게 단위 투여 형태로 투여하는 것으로 되어 있는 뇌혈관 장해의 치료 방법.
    상기 식에서, n은 1 내지 6의 정수이고, X 또는 Y 중 어느 하나는 산소이고, 나머지 하나는 -CH2-이며, R1은 a)
    (상기 식 중, R4및 R5는 독립적으로 불소, 염소, 브롬, 니트로, 트리플루오로메틸, 탄소 원자수 1 내지 6개의 알킬, 탄소 원자수 1 내지 6개의 알콕시, 또는 아릴임), b) 3,4,5-트리메틸페녹시,
    (상기 식 중, R6은 수소, 불소, 염소, 탄소 원자수 1 내지 6개의 알킬, 또는 아릴이고, Z는 -CH2-, -O-, -S-, 또는 -NR7(여기서 R7은 수소, 탄소 원자수 1 내지 6개의 알카노일, 또는 탄소 원자수 1 내지 6개의 알킬임)임),
    (상기 식 중, R8및 R9은 독립적을 수소, 불소, 브롬, 탄소 원자수 1 내지 6개의 알킬, 또는 탄소 원자수 1 내지 4개의 알콕시임), 또는 e)
    (상기 식 중, R8및 R9는 상기 정의한 바와 같음) 중에서 선택되고, R2는 메틸이고, R3은 수소, 탄소 원자수 1 내지 6개의 알킬,
    (여기서, R10은 탄소 원자수 1 내지 4개의 알킬임)이거나, 또는 R2및 R3는 부착되어 있는 질소 원자와 함께 할 경우, 이 기들은 피롤리디닐, 피페리디닐 또는 헥사히드로-1H-아제피닐 고리를 형성한다.
  2. 제1항에 있어서, 뇌혈관 장해가 뇌졸중인 것을 특징으로 하는 치료방법.
  3. 제1항에 있어서, 상기 화합물이 (-)-5α-7α-8β-N-메틸-N-[7-(1-피롤리디닐)-1-옥사스피로[4.5]데크-8-일]-4-벤조푸란아세트아미드인 것을 특징으로 하는 치료방법.
  4. 제1항에 있어서, 상기 화합물 또는 제약상 허용되는 염을 0.001mg 내지 10 mg/kg(체중)/1일으로 투여하는 것을 특징으로 하는 치료 방법.
  5. 제1항의 화합물의 뇌혈관 장해치료의 유효량과 제약상 허용되는 담체의 조합으로 되어 있는 제약 조성물.
  6. 다음 일반식 (I)의 화합물 및 그의 제약상 허용되는 염의 유효 치료량을 뇌혈관 장해의 치료를 요하는 환자에게 단위 투여 형태로 투여하는 것으로 되어 있는 감염치료 방법.
    상기 식에서, n은 1 내지 6의 정수이고, X 또는 Y 중 어느 하나는 산소이고, 나머지 하나는 -CH2-이며, R1은 a)
    (상기 식 중, R4및 R5는 독립적으로 불소, 염소, 브롬, 니트로, 트리플루오로메틸, 탄소 원자수 1 내지 6개의 알킬, 탄소 원자수 1 내지 6개의 알콕시, 또는 아릴임), b) 3,4,5-트리메틸페녹시, c)
    (상기 식 중, R6은 수소, 불소, 염소, 탄소 원자수 1 내지 6개의 알킬, 또는 아릴이고, Z는 -CH2-, -O-, -S-, 또는 -NR7(여기서 R7은 수소, 탄소 원자수 1 내지 6개의 알카노일, 또는 탄소 원자수 1 내지 6개의 알킬임)임),
    (상기 식 중, R8및 R9은 독립적을 수소, 불소, 브롬, 탄소 원자수 1 내지 6개의 알킬, 또는 탄소 원자수 1 내지 4개의 알콕시임), 또는 e)
    (상기 식 중, R8및 R9는 상기 정의한 바와 같음) 중에서 선택되고, R2는 메틸이고, R3은 수소, 탄소 원자수 1 내지 6개의 알킬,
    (여기서, R10은 탄소 원자수 1 내지 4개의 알킬임)이거나, 또는 R2및 R3는 부착되어 있는 질소 원자와 함께 할 경우, 이 기들은 피롤리디닐, 피페리디닐 또는 헥사히드로-1H-아제피닐 고리를 형성한다.
  7. 제6항에 있어서, 상기 화합물이 (-)-5α-7α-8β-N-메틸-N-[7-(1-피롤리디닐)-1-옥사스피로[4.5]데크-8-일]-4-벤조[b]푸란아세트아미드인 것을 특징으로 하는 치료방법.
  8. 제6항에 있어서, 상기 화합물 또는 제약상 허용되는 염을 0.001mg 내지 1 mg/kg(체중)/1일으로 투여하는 것을 특징으로 하는 치료 방법.
  9. 제6항의 화합물의 염증 치료 유효향과 제약상 허용되는 담체의 조합으로 되어 있는 제약 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900005561A 1989-04-21 1990-04-20 뇌혈관 장해치료제로서의 7-치환 아미노-8-치환카르보닐-메틸아미노-1-옥사스피로(4,5)데칸 KR0149491B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019980015878A KR0150182B1 (ko) 1989-04-21 1998-05-02 소염제로서의 7-치환 아미노-8-치환 카르보닐-메틸 아미노-1-옥사스피로(4,5)데칸

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US341336 1989-04-21
US07/341,336 US4965278A (en) 1989-04-21 1989-04-21 7-(substituted)amino)-8-((substituted)carbonyl)-methylamino)-1-oxaspiro[4,5]decanes as diuretics antiiflammatory, and cerebrovascular agents
US341,336 1989-04-21

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1019980015878A Division KR0150182B1 (ko) 1989-04-21 1998-05-02 소염제로서의 7-치환 아미노-8-치환 카르보닐-메틸 아미노-1-옥사스피로(4,5)데칸

Publications (2)

Publication Number Publication Date
KR900015726A true KR900015726A (ko) 1990-11-10
KR0149491B1 KR0149491B1 (ko) 1998-10-15

Family

ID=23337122

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900005561A KR0149491B1 (ko) 1989-04-21 1990-04-20 뇌혈관 장해치료제로서의 7-치환 아미노-8-치환카르보닐-메틸아미노-1-옥사스피로(4,5)데칸

Country Status (10)

Country Link
US (1) US4965278A (ko)
EP (1) EP0393696A3 (ko)
JP (1) JP3070930B2 (ko)
KR (1) KR0149491B1 (ko)
AU (1) AU622312B2 (ko)
CA (1) CA2014957A1 (ko)
IE (1) IE64852B1 (ko)
NZ (1) NZ233376A (ko)
PT (1) PT93806B (ko)
ZA (1) ZA903016B (ko)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5317028A (en) * 1992-09-08 1994-05-31 Warner-Lambert Co. 7-((substituted)amino)-8((substituted)carbonyl)-methylamino-1-oxaspiro(4,5)decanes useful in Parkinson's disease, dystonia, and other movement disorders
US5369120A (en) * 1993-07-28 1994-11-29 Warner-Lambert Company Pharmaceutical composition of 7-((substituted)amino-8-((substituted)carbonyl)-(methylamino)-1-oxasp iro(4,5)decanes and L-dopa
US5489607A (en) * 1995-02-16 1996-02-06 Warner-Lambert Company Use of enadoline in the treatment of benign prostatic enlargement
US6239154B1 (en) 1996-03-08 2001-05-29 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US5763445A (en) 1996-03-08 1998-06-09 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US20020188268A1 (en) 1999-06-30 2002-12-12 Mark James Kline Elastomeric side panel for use with convertible absorbent articles
US5859043A (en) * 1996-06-11 1999-01-12 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for maintaining kidney function during surgery or severe trauma under general anesthesia
US6468971B1 (en) 1997-03-05 2002-10-22 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Maintaining kidney function during surgery or trauma
BR9810706A (pt) * 1997-07-14 2000-08-08 Adolor Corp Processo para a prevenção ou tratamento do prurido em um mamìfero em necessidade de tal prevenção ou tratamento
US5760023A (en) * 1997-07-14 1998-06-02 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
GB0123571D0 (en) * 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
US7964800B2 (en) * 2006-05-25 2011-06-21 Fujikura Ltd. Printed wiring board, method for forming the printed wiring board, and board interconnection structure

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT376669B (de) 1982-11-26 1984-12-27 Laevosan Gmbh & Co Kg Verfahren zur herstellung neuer thienylessigsaeureamid-derivate und pharmazeutisch vertraeglicher saeureadditionssalze davon
US4598087A (en) 1983-12-06 1986-07-01 Warner-Lambert Company Substituted trans-1,2-diaminocyclohexyl amide compounds
US4618621A (en) * 1984-09-21 1986-10-21 The Upjohn Company Method for treating medical conditions involving cerebral ischemia
US4737493A (en) * 1985-07-01 1988-04-12 Warner-Lambert Company 7-((substituted)amino)-8-((substituted)carbonyl)-methylamino)-1-oxaspiro(4,5)decanes as analgesic agents
US4663343A (en) 1985-07-19 1987-05-05 Warner-Lambert Company Substituted naphthalenyloxy-1,2-diaminocyclohexyl amide compounds
GB8618188D0 (en) 1986-07-25 1986-09-03 Ici Plc Diamine compounds
EP0258095B1 (fr) 1986-08-12 1991-06-12 Roussel-Uclaf Nouveaux dérivés de la décahydroquinoléine, leur procédé de préparation et les nouveaux intermédiaires obtenus, leur application à titre de médicaments et les compositions pharmaceutiques les renfermant
DE3781627T2 (de) 1986-08-21 1993-05-06 Roussel Uclaf Indanderivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, diese enthaltende pharmazeutische zusammensetzungen und erhaltene zwischenprodukte.
DE3767816D1 (de) 1986-09-02 1991-03-07 Zambeletti Spa L 1-acylsubstituierte piperidinderivate.
US4876269A (en) 1986-09-10 1989-10-24 E. I. Du Pont De Nemours And Company Benoz-fused cycloalkane trans-1,2-diamine derivatives
EP0261842B1 (en) 1986-09-17 1990-11-22 Dr. Lo. Zambeletti S.p.A. N1-acylated-(1-(phenyl or benzyl))-1,2-ethylene diamines
US4906655A (en) * 1989-01-24 1990-03-06 Warner-Lambert Company Novel 1,2-cyclohexylaminoaryl amides useful as analgesic agents

Also Published As

Publication number Publication date
IE901422L (en) 1990-10-21
ZA903016B (en) 1991-12-24
KR0149491B1 (ko) 1998-10-15
PT93806A (pt) 1990-11-20
JP3070930B2 (ja) 2000-07-31
EP0393696A2 (en) 1990-10-24
US4965278A (en) 1990-10-23
CA2014957A1 (en) 1990-10-21
NZ233376A (en) 1999-08-30
PT93806B (pt) 1996-09-30
IE64852B1 (en) 1995-09-06
JPH02292218A (ja) 1990-12-03
EP0393696A3 (en) 1992-09-02
AU5368690A (en) 1990-10-25
AU622312B2 (en) 1992-04-02

Similar Documents

Publication Publication Date Title
KR880012218A (ko) 캘폰 유도체를 사용한 다발성 경화증의 치료방법
KR900015726A (ko) 이뇨제, 소염제 및 뇌혈제관제로서의 7-치환 아미노-8-치환 카르보닐-메틸아미노-1-옥사스피로[4,5]데칸
KR920700200A (ko) 19-노르-비타민 d 화합물
RU96115142A (ru) Производные 5-(2-имидазолиниламино)бензимидазола, их получение и применение в качестве агонистов альфа-2-адреноцепторов
MY102908A (en) Isoxazole and furan derivatives, their preparation and use as antiviral agents.
KR880012217A (ko) 캘콘 유도체를 사용한 종량 조직의 증식 억제방법
KR950031068A (ko) 골다공증의 복합 치료
KR880012227A (ko) 도파민 수용체 길항제의 신규사용법
AR020016A2 (es) Compuestos derivados de la eritromicina, composiciones que los contienen, uso de los mismos para preparar un medicamento
KR930019655A (ko) 종양치료 조성물 및 치료방법
KR890701587A (ko) 골 손실에 관련된 질병 치료용 이미다조(1,2-a)(피리
DE60014916D1 (de) Die Verwendung eines Benzimidazoles zur Herstellung eines Medikamentes zur Krebsvorbeugung
KR950007848A (ko) (S)-(-)-α-에틸-2-옥소-1-피롤리딘아세트아미드를 사용한 불안치료방법
KR900005978A (ko) 키니딘, 아르테미시닌 및 이의 유도체를 사용한 항말라리아 조성물 및 치료방법
ATE1418T1 (de) 1-hydrocarbyloxyphenyl-1.2-diphenylalkenderivate, ihre herstellung und sie enthaltende pharmazeutische zusammensetzung.
ES2059755T3 (es) Derivados organicos de hidrazina para uso farmaceutico.
DE69312567D1 (de) 2-Formylpyridin-Thiosemicarbazonderivate, ihre Herstellung und ihre Verwendung als Antitumor Mittel
ES8501410A1 (es) Un procedimiento para la preparacion de nuevos derivados de fosfolipidos.
ATE27160T1 (de) Tri- und tetracyclische imidazo(1,5a)(1,4)benzodiazepin-1-carbonsaeurederivate.
KR880007498A (ko) 중추작용 근이완제
KR920019348A (ko) 탄산탈수효소 억제제 및 β-아드레날린 길항제의 배합물을 포함하는 안과용 조성물
KR880007462A (ko) 빈뇨치료용 프로피오페논 유도체
ES2059348T3 (es) Composicion farmaceutica para el tratamiento de cataratas.
KR880004810A (ko) 소화성 궤양 치료제
KR910007887A (ko) W-페녹시-헤테로사이클릭 화합물

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee